Test Code LAB3725 clonoSEQ
Clinical System Name
clonoSEQ
Sample Requirements
Preferred Specimen: Bone Marrow
Container(s): Lavender/EDTA
Preferred Vol: >2.0 mL
Minimum Vol: >1.0 mL
Specimen: Fresh Peripheral Blood
Container(s): Lavender/EDTA
Preferred Vol: 2.0 mL
Minimum Vol: >2.0 mL
Processing Instructions
Reject due to:
Spin: N
Aliquot: N
Temp: RT or 2 - 4 C (see Storage Location instructions)
Storage Location: During business hours, call Send Outs for special handling. If received after hours or on weekends, place sample in the CPA 1 refrigerator's Send Outs rack.
Off-site collection:
Stability
Specimen Type | Temperature | Time |
Bone Marrow | Room temp | 4 d |
Refrigerated | 7 d | |
Frozen | ||
Peripheral Blood | Room temp | 4d |
Refrigerated | 7d | |
Frozen |
Availability
STAT | Performed | TAT |
N | M - F | 7 - 14 d |
Performing Laboratory
Adaptive Biotechnologies Corporation
Attention: Clinical Services
1165 Eastlake Avenue East
Seattle, WA 98109
Phone Number: (888) 552-8988
Intake Hours: Monday - Friday 08:00 - 17:00 PST
Department
Department: Send Outs/Genetic
Phone Number: (206) 987-2563
Methodology
Method: PCR and Next-Generation Sequencing
Analytical Volume: >2.0 mL Bone Marrow
Limitations:
Send Out Instructions
Reference Test Name: | clonoSEQ |
Reference Test Code: | N/A |
Instructions: | During business hours, call Send Outs for special handling. If received after hours or on weekends, place sample in the CPA 1 refrigerator's Send Outs rack. Send Monday through Friday via Delivery Express. Adaptive Biotechnologies can receive samples up until 1700 PST. |
Description
The clonoSEQ® Clonality (ID) Test determines the clonal diversity of a sample and can also be used to identify the trackable immune receptor sequence(s) of a lymphoid clone. Diagnostic samples are typically used, but other samples with high disease load (e.g., relapse) are also acceptable.
clonoSEQ is an FDA-cleared in vitro diagnostic (IVD) test service for use in B-cell acute lymphoblastic leukemia and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers and validated
sample types as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies.
Reference Ranges
Interpretive report provided.